We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

BRUKER

BRUKER offers high-performance scientific instruments and high-value analytical and diagnostic solutions that enable ... read more Featured Products: More products

Download Mobile App




Skin Infections Confirmed as a Cause of Acute Rheumatic Fever

By LabMedica International staff writers
Posted on 05 Jan 2022
Infection with group A streptococcus (GAS) can trigger an immune-mediated response in a small minority of people, resulting in acute rheumatic fever (ARF). More...
ARF produces an inequitable burden of disease, with the highest rates in low and middle-income countries and among some, often indigenous-minority populations living in high-income countries.

Group A Streptococcus (GAS; Streptococcus pyogenes) is a bacterium which can colonize the throat, skin and anogenital tract. It causes a diverse range of skin, soft tissue and respiratory tract infections. GAS can occasionally cause infections that are extremely severe. Invasive GAS (iGAS) is an infection where the bacteria is isolated from a normally sterile body site, such as the blood.

Infectious disease specialists at the University of Otago Wellington (Wellington, New Zealand) and their colleagues carried out a retrospective analysis used pre-existing administrative data. Throat and skin swab data (1,866,981 swabs) from the Auckland region, New Zealand and antibiotic dispensing data were used (2010–2017). Incident ARF cases were identified using hospitalization data (2010–2018). The risk ratio (RR) of ARF following swab collection was estimated across selected features and timeframes. Antibiotic dispensing data were linked to investigate whether this altered ARF risk following GAS detection.

Swabs were cultured onto tryptic soy sheep blood agar and incubated for 48 hours at 37 °C in 5% CO2. Plates were reviewed after 24 and 48 hours of incubation, and colonies indicating beta-hemolytic streptococci were identified. Prior to 2012, streptococcal grouping latex was used to identify beta-hemolytic streptococci. From 2012 onwards, MALDI-TOF MS Biotyper (Bruker, Karlsruhe, Germany) was used. Emm-typing for GAS strain identification is not used in routine diagnostic testing, so strain-typing data were unavailable.

The investigators reported that ARF risk increased following GAS detection in a throat or skin swab. Māori and Pacific Peoples had the highest ARF risk 8–90 days following a GAS-positive throat or skin swab, compared with a GAS-negative swab. During this period, the RR for Māori and Pacific Peoples following a GAS-positive throat swab was 4.8 and following a GAS-positive skin swab, the RR was 5.1. Antibiotic dispensing was not associated with a reduction in ARF risk following GAS detection in a throat swab (antibiotics not dispensed (RR: 4.1), antibiotics dispensed (RR: 4.3), or in a skin swab (antibiotics not dispensed (RR: 3.5), antibiotics dispensed (RR: 2.0).

Michael Baker, MBChB, FNZCPHM, FAFPHM, FRACMA, DComH, DObst, a Professor of Public Health and a senior author of the study, said, “This study is a major breakthrough in understanding the causes of acute rheumatic fever. It is the world’s first study to confirm that the risk of rheumatic fever rises after a GAS skin infection in a similar way to how it does after a GAS sore throat. Because acute rheumatic fever is an uncommon disease and few countries have comprehensive linked health data, no previous study has been able to quantify the rheumatic fever risk following a laboratory-confirmed infection.”

The authors concluded that prompt antibiotic treatment of GAS infections in groups with a known high risk of ARF is required to terminate the infective process, reducing the risk of poor outcomes, and to limit GAS transmission. Targeted sore throat management interventions should remain a key strategy in the prevention of ARF. The study was published on December 9, 2021 in the journal BMJ Global Health.

Related Links:
University of Otago Wellington
Bruker



New
Gold Member
Collection and Transport System
PurSafe Plus®
Collection and Transport System
PurSafe Plus®
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.